Case Type: Mergers & Acquisitions

First Miami Bancorp, Inc. (OTC: FMIA), relating to its proposed sale to United Community Banks, Inc. Under the terms of the agreement, FMIA shareholders are expected to receive 10.2685 shares of United per share they own.

NuVasive, Inc. (NASDAQ: NUVA), relating to its proposed sale to Globus Medical, Inc. Under the terms of the agreement, NUVA shareholders are expected to receive 0.75 shares of Globus per share they own.

Cardiovascular Systems, Inc. (NASDAQ: CSII), relating to its proposed sale to Abbott Laboratories. Under the terms of the agreement, CSII shareholders are expected to receive $20.00 in cash per common share they own.

Sumo Logic, Inc. (NASDAQ: SUMO), relating to its proposed sale to affiliates of Francisco Partners. Under the terms of the agreement, SUMO shareholders are expected to receive $12.05 in cash per share they own.

Oak Street Health, Inc. (NYSE: OSH), relating to its proposed sale to CVS Health. Under the terms of the agreement, OSH shareholders are expected to receive $39.00 in cash per share they own.

Argo Group International Holdings, Ltd. (NYSE: ARGO), relating to its proposed sale to Brookfield Reinsurance. Under the terms of the agreement, ARGO shareholders are expected to receive $30.00 in cash per share they own

AlerisLife Inc. (NASDAQ: ALR), relating to its proposed sale to APB Acquisition LLC. Under the terms of the agreement, ALR shareholders are expected to receive $1.31 in cash per share they own.

Chembio Diagnostics, Inc. (NASDAQ: CEMI), relating to its proposed sale to Biosynex SA. Under the terms of the agreement, CEMI shareholders are expected to receive $0.45 in cash per share they own.

Atlas Technical Consultants, Inc. (NASDAQ: ATCX), relating to its proposed sale to GI Partners. Under the terms of the agreement, ATCX shareholders are expected to receive $12.25 in cash per share they own.

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE), relating to its proposed acquisition by Sun Pharmaceutical Industries Limited. Under the terms of the tender offer, CNCE shareholders are expected to receive $8.00 in cash and one non-tradeable CVR worth a deferred $3.50 in cash per share they own.